Long-serving Roche chief executive Severin Schwan is stepping down, to be replaced next March by Thomas Schinecker, currently head of diagnostics at the Swiss group. Schwan (pictured above ...

In some respects, the new approval is a key milestone for Roche, coming after years of effort at the diagnostics giant to build its presence in the digital pathology category. That dates back to ...

Why DEI Works for Business By ROD COTTON Perhaps it’s no coincidence that the tumultuous events of the past few weeks fell on ...

UBS analyst Matthew Weston upgraded Roche Holding (OTC:RHHBY) stock from Neutral to Buy, adjusting the price target to CHF 338.00, up from the previous CHF 300.00. The upgrade comes as the stock ...

1 Day RHHBY 2.56% DJIA 0.77% S&P 500 1.04% Health Care/Life Sciences 0.10% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

To run the app without installing, download Standalone.zip below, unzip, then run SidebarDiagnostics.exe. Please note that the Standalone build will not auto-update.